Immunosuppression and Graft Rejection in Living-Related HLA-Identical Renal Transplantation: The RADOVFULL Study.
We aimed to describe the immunosuppressive regimens and graft rejection rates in living-related HLA-identical (LR HLAid) renal transplantation. We performed a retrospective multicenter analysis of the French national database for LR HLAid renal transplantations performed between 2002 and 2012. Univariate and multivariate analysis were performed to determine risk factors for graft rejection in LR HLAid recipients. 27.218 renal transplantations were performed of whom 163 had a LR HLAid donor. Concerning immunosuppressive treatment, less than 60% of the cohort had induction therapy with polyclonal or monoclonal antibodies, 28% did not receive calcineurin inhibitors and 36% did not receive steroids in maintenance. Biopsy-proven acute rejection was diagnosed in 21 patients (12.9%). Rejection occurred on an average of 24 months after transplantation, in 28.5% of the cases after minimization of immunosuppression. Factors associated with rejection were age of recipient (OR = 0.91[0.84-0.96], p=0.003), the body mass index of donors (OR = 1.22[1.04-1.46], p=0.01) and minimization of immunosuppression (OR = 26.2[5.48-166.6], p < 0.001). Overall and graft survival rates were not statistically different according to rejection at 1, 5 and 10 years post transplantation. Minimization of immunosuppression should be done with caution in LR HLAid renal transplantations.